Coxevac
Opinion
On 15 February 2023, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion1, recommending the granting of an extension to the terms of the marketing authorisation for the veterinary medicinal product Coxevac. The marketing authorisation holder for this veterinary medicinal product is CEVA Santé Animale.
Coxevac is currently authorised as suspension for injection for cattle and goats. The extension concerns the addition of sheep as a target species.
Detailed conditions for the use of this product are described in the summary of product characteristics (SPC) which will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.
1 Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.
Key facts
| Name |
Coxevac |
| Agency product number |
EMEA/V/C/000155 |
| International non-proprietary name (INN) or common name |
|
| Species |
Goats
Cattle
|
| Active substance |
|
| Date opinion adopted |
15/02/2023 |
| Company name | |
| Status |
Positive |
| Application type |
Post-authorisation |